Researchers Combined Therapies for Kidney Cancer

A study published September 9, 2026, details how combining two treatments increases tumor cell death.

Updated on Sept. 30, 2026 in Cancer

A close-up view of a glass laboratory vial containing a vibrant blue chemical solution on a brushed steel surface, highlighting medical research precision. — Researchers have identified that combining belzutifan with recombinant TRAIL successfully overcomes resistance in clear cell renal cell carcinoma, according to findings published September 9, 2026. AI Illustration. Upload story photo >

Live Poll

Do you trust laboratory findings on cancer treatments before they complete human clinical trials?

Scientists developed a new combination therapy for clear cell renal cell carcinoma by pairing the FDA-approved drug belzutifan with recombinant TRAIL. This approach aims to overcome tumor resistance often seen in patients treated with belzutifan alone.

Why it matters

Clear cell renal cell carcinoma is linked to VHL gene mutations that lead to increased HIF-2-alpha levels, which eventually cause tumors to resist standard treatment. This study provides a potential path to bypass that resistance and improve therapeutic outcomes.

The study demonstrates that belzutifan reduces HIF-2-alpha protein to free death receptors, allowing introduced recombinant TRAIL to bind effectively to cancer cells. These results represent laboratory-based findings from the University of Notre Dame and the University of Galway.

The players

University of Notre Dame

This is a private Catholic research university located in Indiana that served as a primary institution for the study.

University of Galway

This is a public research university in Ireland that collaborated on the development of the combination cancer therapy.

The details

Belzutifan works by reducing HIF-2-alpha levels, a protein elevated by VHL gene mutations that traps natural TRAIL proteins and death receptors inside the cell. By freeing these receptors, the research team successfully enabled recombinant TRAIL to target and kill the cancer cells.

September 09, 2026: The research findings were originally published.
September 30, 2026: The article was republished by news.nd.edu.

Cancer
Sept. 24
FDA Approved New Kidney Cancer Treatment Combination
Cancer
Sept. 23
Texas A&M Researchers Identified Cancer Cell Pathway
Cancer
Sept. 24
Vaccine Misinformation Threatened Cancer Treatment Progress

The Big Picture

This study follows the precedent of peer-reviewed oncology research published in the Proceedings of the National Academy of Sciences to validate novel combination treatments.

This research is in the laboratory phase and does not currently change existing treatment protocols for patients. It highlights a future pathway for clinical trials that could eventually offer new options for those who develop resistance to belzutifan.

The takeaway

The study illustrates how overcoming cellular resistance mechanisms is a critical hurdle in modern oncology development. Patients should continue to consult their oncologists regarding currently approved therapies while new combinations advance through clinical trials.